Rheumatoid Arthritis - Lovastatin Therapy Study
ARA02: A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the treatment of mildly active Rheumatoid Arthritis
Protocol ID
Protocol Description
This study will look at the effects of a drug called Lovastatin in the treatment of patients with mildly active rheumatoid arthritis (RA). Lovastatin is one of the “statin” drugs approved by the FDA for the treatment of high cholesterol, but it is currently not approved for treating RA. There is evidence from laboratory studies that Lovastatin may be beneficial in the treatment of mildly active RA. One purpose of this study is to determine if Lovastatin is effective in reducing the inflammation that is seen in patients with mildly active RA. Another purpose is to see if it is safe for treatment of mildly active RA. This study will look at the effects of Lovastatin by comparing subjects with RA who receive the study drug, Lovastatin, to those who do not.
Eligibility Criteria
Patients with mildly active rheumatoid arthritis (RA)
Primary Investigator(s)
- Cynthia Aranow, MD
Contact Information
(516) 562-2401
skandasami@nshs.edu